Skip to main content
Top
Published in: Hepatology International 2/2022

01-04-2022 | Hepatitis | Letter to the Editor

Histology activity index: a benchmark for decision making

Authors: Shaheena Parveen, Avinash Tiwari, Aadil Ashraf

Published in: Hepatology International | Issue 2/2022

Login to get access

Excerpt

This year, the Hepatology International published a much-needed guideline of a challenging disease, i.e., autoimmune hepatitis and that also with reference to the Asia Pacific region titled: ‘The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis’ [1]. The update in the article was the evolution of the indications for treatment as per different guidelines. There has been better understanding regarding the time duration for withdrawal of treatment and disease remission. Unlike clinical remission or biochemical remission which could be sometimes misleading and also comes with increased risk of relapse, histological remission is preferred [1]. Hepatitis score has been used for histological remission. Initially introduced by Knodell et al. [2] in 1981, hepatitis score has also undergone marked changes. However, this scoring system score also includes fibrosis and thus limiting the accuracy of assessment of ongoing inflammation. In 1995, going one step forward, Ishak et al. came with modification of the original histological activity index (HAI). The activity score was divided as: (a) inflammation with maximum score of 18 and (b) fibrosis with maximum score of 4 [3]. In 2015, EASL Autoimmune Hepatitis guidelines [4] came with the decision regarding the use of modified (m) HAI. According to mHAI, a score of 4 or more than 4 is the best indicator of on-going active inflammation [5]. In 2021, APASL came with an updated HAI score cut-off that is above 3. It is good to see the score lowered from 4 to 3 for, as it has always been tough for a treating physician to take a decision regarding withdrawal of medication which would eventually come with risk of relapse and further worsening of the disease. However, in page no. 236 [1] under the heading—Duration of Treatment there is likely a typo error, i.e., it has been mentioned mHAI > 3 which should be mHAI < 3 for alleviation of inflammation. …
Literature
1.
go back to reference Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, et al. The Asian Pacific association for the study of the liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223–257CrossRefPubMed Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, et al. The Asian Pacific association for the study of the liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223–257CrossRefPubMed
2.
go back to reference Krishna M. Histological grading and staging of chronic hepatitis. Clin Liver Dis. 2021;17(4):222–226CrossRef Krishna M. Histological grading and staging of chronic hepatitis. Clin Liver Dis. 2021;17(4):222–226CrossRef
3.
go back to reference Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatol Baltim Md. 2000;31(1):241–246CrossRef Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatol Baltim Md. 2000;31(1):241–246CrossRef
4.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004CrossRef
5.
go back to reference Moon AM, Spiritos Z, King LY, Barritt AS. Immunosuppression in autoimmune hepatitis: is there an end game? Am J Gastroenterol. 2020;115(4):498–501CrossRefPubMed Moon AM, Spiritos Z, King LY, Barritt AS. Immunosuppression in autoimmune hepatitis: is there an end game? Am J Gastroenterol. 2020;115(4):498–501CrossRefPubMed
Metadata
Title
Histology activity index: a benchmark for decision making
Authors
Shaheena Parveen
Avinash Tiwari
Aadil Ashraf
Publication date
01-04-2022
Publisher
Springer India
Published in
Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10290-8

Other articles of this Issue 2/2022

Hepatology International 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.